Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children ...

Novo Nordisk's Awiqli® has received FDA approval as the first once-weekly basal insulin for children aged 10 and above with type 2 diabetes, offering a treatment that reduces injection frequency from seven times a week to once weekly.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.